ARTICLES BY JAMES MORRIS
Moving Beyond Human Error In Biopharma Investigations And CAPA Programs11/16/2020
Human performance improvement requires special focus and deliberate action by management to move from an old construct of investigating error as a human failure to an new construct where error is a symptom of a problem to be understood, linked to the context in which the error took place, and it is the starting point of the investigation, not its conclusion.
Human Performance In Biopharma Operations — Your Problem Isn’t Error11/9/2020
Part 1 of a two-part roundtable discusses key drivers for human performance improvement, lean manufacturing and human performance programs, and perspectives on human performance in the context of the rapid scale-up and production of COVID-19 therapeutics and vaccines.
5 Operational Priorities For Pharmas In The Wake Of COVID-197/20/2020
Consider Gilead’s ramp-up of remdesivir under FDA Emergency Use Authorization, or the efforts of companies racing to bring vaccines and therapeutics for COVID-19 through clinical development, safety and efficacy trials at speeds not seen before. The analogy of changing a tire while driving the vehicle is well known — now picture doing so at 7,000 rpm!
Applying The Johari Window To Manage Biopharma Supply Chain Risk2/14/2020
The recalls of generic versions of the drug valsartan and related products losartan and irbesartan due to nitrosamine impurities have put the spotlight on sourcing strategies and the globalization of the pharma supply chain. The Johari Window model can help minimize the risk inherent in a complex supply chain.
Recommendations For Managing Complexity In Biopharma Operations1/21/2020
There's a tendency in biopharma operations to make things more complex than they need to be. More content in an SOP, additional signatures, new forms, and control loops don't necessarily equate to better.
Beyond Human Error: Are Blunt- Or Sharp-End Decisions More Important In The Life Sciences?3/27/2019
Decisions made upstream in the supply chain can have enormous repercussions downstream at the bedside or in the home, where medications are administered. How do we guarantee that the big and seemingly small decisions being made with each batch manufactured will be the “right” ones when there is so much inherent variability around us?